2026.Apr.09

Corporate

OBI Presents Obrion™ ADC Technologies at AntibodyChina 2026 in Shanghai
Highlighting Scalable Manufacturing and Bispecific Dual-Payload Design

OBI Pharma (4174.TWO) was invited to deliver a presentation at AntibodyChina 2026: The 9th Antibody Therapeutics & ADC Focus Summit, held in Shanghai, China from April 8 to 9.

HOMEWhat’s NewNewsOBI Presents Obrion™ ADC Technologies at AntibodyChina 2026 in Shanghai Highlighting Scalable Manufacturing and Bispecific Dual-Payload Design

Back to List

This article is password protected.

To view the content, please enter your password in the field below

2026.Apr.02

OBI Participated in BIO-Europe Spring®, Advancing International Business Development Engaged with Multiple Global Pharma Companies for Licensing Discussions

2026.Apr.15

OBI Pharma Announces Ten Poster Presentations at the AACR 2026 Annual Meeting for GlycOBI® Glycan-based Site-Specific Antibody-Drug Conjugates (ADCs): Mono and Bi-Specific (inc. Dual payload) and Obrion™ ADC enabling technologies